Lack of Efficacy of 24-h Infusional Topotecan in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Trial

Author： Markman M. Blessing J.A. DeGeest K. Morgan M. Look K.Y. Herzog T.J. Rose P.G.

Publisher： Elsevier

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.75, Iss.3, 1999-12, pp. : 444-446

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial

By Markman M. Blessing J.A. Moore D. Ball H. Lentz S.S.

Gynecologic Oncology, Vol. 69, Iss. 3, 1998-06 ,pp. : 226-229

Elsevier

Access to resources Recommend Favorite

Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report

By Markman M. Iseminger K.A. Hatch K.D. Creasman W.T. Barnes W. Dubeshter B.

Gynecologic Oncology, Vol. 62, Iss. 1, 1996-07 ,pp. : 4-6

Academic Press

Access to resources Recommend Favorite

Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

By Markman M. Blessing J.A. Alvarez R.D. Hanjani P. Waggoner S. Hall K.

Gynecologic Oncology, Vol. 77, Iss. 1, 2000-04 ,pp. : 112-115

Elsevier

Access to resources Recommend Favorite

Phase II Trial of CI-958 in Recurrent Platinum-Refractory Ovarian Carcinoma - A Gynecologic Oncology Group Study

By Hoffman M.A. Blessing J.A. Morgan M.

Gynecologic Oncology, Vol. 79, Iss. 3, 2000-12 ,pp. : 463-465

Elsevier

Access to resources Recommend Favorite

Phase I Trial of Ifosfamide and 24-h Infusional Paclitaxel in Pelvic Malignancies: A Gynecologic Oncology Group Study

By Markman M. Spriggs D. Burger R.A. Carson L.F. Lentz S.S. Gallion H.

Gynecologic Oncology, Vol. 80, Iss. 3, 2001-03 ,pp. : 359-363

Elsevier

Access to resources Recommend Favorite